Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of F-627 for prevention of chemotherapy-induced neutropenia in women with breast cancer
2016-001930-93Phase 3Completed
- Sponsor
- Evive Biotech
- Start
- Sep 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced neutropenia (CIN) and breast cancer comparing F-627 plus myelotoxic chemotherapy with Placebo plus myelotoxic chemotherapy (2 arms). Primary endpoint: Duration of grade 4 neutropenia in cycle 1. Started Sep 2016; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
chemotherapy-induced neutropenia (CIN)breast cancer
Beyond the preview
Go deeper on 2016-001930-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001930-93.